Next-generation immune profiling - beyond blood cancer cells

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Current diagnostic classifications for hematological malignancies, like the WHO/ICC 2022, primarily focus on cancer cell morphology.
• This approach neglects the crucial role of the tumor immune microenvironment, limiting diagnostic precision and therapeutic strategies.

Purpose of the Study:

• To highlight the need for integrating immune profiling into hematological malignancy classification.
• To advocate for the standardization of immune profiles and the adoption of next-generation technologies for improved diagnostics and precision immunotherapies.

Main Methods:

• Review of current diagnostic frameworks for hematological malignancies.
• Discussion of emerging next-generation profiling technologies such as single-cell sequencing, spatial transcriptomics, and advanced cytometry.
• Emphasis on the potential of immune profiling for therapeutic targeting and biomarker discovery.

Main Results:

• The exclusive focus on cancer cell characteristics in current classifications leads to a disconnect with the immune environment.
• The immune compartment offers significant potential for novel therapeutic targets (e.g., bispecific antibodies) and patient outcome biomarkers.
• Standardized immune profiling can enhance disease classification and enable precision immunotherapy.

Conclusions:

• Next-generation immune profiling is essential for advancing the classification of hematological malignancies beyond cancer cells.
• Integrating immune insights will facilitate the development of tailored therapies and improve clinical decision-making.
• Adoption of advanced profiling technologies into clinical workflows is critical for precision oncology.